Urothelial Cancer
A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment - DS1062-328
- Details
ClinicalTrials.gov ID:
NCT07129993
Diagnosis Type:
NA
USOR Number:
- Address
,
P: